MedTrace Logo

Phase 2 Study of RSLV-132 in Subjects With Long COVID

NCT04944121 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2024-05-29

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome

Conditions

  • Post-acute Corona Virus 19 (COVID-19) (Long COVID)

Interventions

DRUG

RSLV-132

10 mg/kg RSLV-132 administered by intravenous infusion

DRUG

Sodium Chloride 0.9%

0.9% sodium chloride administered by intravenous infusion

Sponsors & Collaborators

  • Resolve Therapeutics

    lead INDUSTRY

Principal Investigators

  • James Posada · Resolve Therapeutics LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-25
Primary Completion
2023-10-31
Completion
2023-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04944121 on ClinicalTrials.gov